Zenas BioPharma (ZBIO) Asset Utilization Ratio (2024 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Asset Utilization Ratio of 0.03 for Q4 2025, up 119.2% year-over-year from 0.01 in Q4 2024, and down 41.89% quarter-over-quarter from 0.05 in Q3 2025.
Zenas BioPharma (ZBIO) Asset Utilization Ratio (2024 - 2026) Analysis & Trends
Zenas BioPharma's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.03 for Q4 2025.
- In Q4 2025, Asset Utilization Ratio rose 119.2% year-over-year to 0.03; the TTM figure through Dec 2025 stood at 0.03 (up 119.2% YoY), while the FY2025 annual figure was 0.03, up 16.28% from the prior year.
- Asset Utilization Ratio for Q4 2025 stood at 0.03, down from 0.05 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.05 in Q3 2025, with the low at 0.01 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.05 |
| Jun 30, 2025 | 0.05 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.01 |